Archive for the ‘VIP Receptors’ Category

miR-196, which is highly expressed in intestinal epithelia of patients with CD, downregulates the IRGM protective variant (c313C), but not the risk associated variant/SNP (c313T) in a tissue specific manner, highlighting the importance of target mRNA polymorphisms in miRNA mediated regulation [Brest 2011]

Wednesday, November 17th, 2021

miR-196, which is highly expressed in intestinal epithelia of patients with CD, downregulates the IRGM protective variant (c313C), but not the risk associated variant/SNP (c313T) in a tissue specific manner, highlighting the importance of target mRNA polymorphisms in miRNA mediated regulation [Brest 2011]. NOD2 analysis of NOD2 3-UTR reveals 11 putative miRNA binding sites that include 2 putative miR-192 Atopaxar hydrobromide binding sites, implicating miRNAs in the regulation of NOD2 expression and inflammatory responses [Chuang 2014]. miRNAs to canonical pathways associated with IBD pathogenesis. In this review, we summarize and discuss the miRNA expression signatures associated with IBD in tissue and peripheral blood, Atopaxar hydrobromide highlight miRNAs with potential future clinical applications as diagnostic and therapeutic targets, and provide an outlook on how to develop miRNA based therapies. 2008], and increasing worldwide IBD incidence Atopaxar hydrobromide [Molodecky and Atopaxar hydrobromide Kaplan, 2010] leave gaps in our understanding of IBD heritability and, simultaneously, highlight the importance of the environment in modifying the development and progression of IBD. Current and future treatments are designed primarily to target the inflammatory cascade as a mechanism to abate continuous disease activity. In order to develop novel therapeutic and diagnostic strategies, further understanding of underlying molecular pathophysiological mechanisms of host disease activation is required. In this era of genome wide association studies (GWAS), epigenetics has only recently emerged as a mechanistic layer for the complexities of gene expression regulation. Results from studies to date indicate that GWAS account for 23% and 16% of the heritability in CD and UC, respectively [Khor 2011]. The missing heritability is likely derived from genetic, epigenetic and nongenetic (including environmental) components. Epigenetics is the study of modifications in regulation of gene expression that occur without Rabbit polyclonal to FBXO42 change to DNA sequence and operates at the interface between environment and heritable molecular and cellular phenotypes. MicroRNAs (miRNAs) are single stranded, evolutionary conserved, 18C24 nucleotide long unique class of noncoding RNAs that exert epigenetic post-transcriptional effects on gene regulation. miRNAs bind to complementary 3 untranslated regions (UTRs) of targeted protein-encoding messenger RNAs (mRNAs), resulting in decreased stability and repression of translation. Investigations into the biologic function of miRNAs have discovered an emerging common theme of adapting to physiologic and pathophysiologic environmental stresses and restoring or altering gene expression in fully differentiated tissues [Leung and Sharp, 2010; Mendell and Olsen, 2012] Recent studies have identified distinct tissue and peripheral blood miRNA expression profiles in IBD. Atopaxar hydrobromide Analyses to validate key miRNA regulated pathways in cell based and various animal models of experimentally induced IBD have only recently begun to elucidate the functional importance of miRNAs in IBD pathogenesis, but already provide clear evidence of GWAS susceptibility gene overlap. As more evidence and knowledge of miRNA function and dysregulation in IBD is accrued, the opportunity for novel miRNA based biomarkers and therapeutics is rapidly approaching. The present review aims to summarize the current literature on miRNAs in IBD and to explore the opportunities and limitations in utilizing miRNAs as biomarkers and therapeutic targets in patients with IBD. miRNA general overview Since the first discovery of miRNA in 1993 [Lee 1993; Wightman 1993], the identification of protein-coding targeting miRNA homologs across many vertebrate species has confirmed an evolutionary conserved mechanism of post-transcriptional gene regulation [Pasquinelli 2000]. To date, there are now over 2500 known mature human miRNA transcripts [miRbase release 20]. miRNAs are transcribed from intronic, intergenic or exonic DNA into a hairpin-stem and loop primary transcript-miRNA (pri-miRNAs). After enzymatic maturation and transport into the cytoplasm, a single strand is loaded into the RNA-induced silencing complex (RISC) containing an Argonaute protein, the catalytically active RNase, forming a mature miRNA complex capable of silencing mRNA 3-UTR binding. The mature miRNA:RISC silences target gene mRNA by binding the miRNA seed sequence, 6C8 nucleotides with extensive, but not necessarily completely complementary sequences, to the 3-UTR of the mRNA. The binding results in mRNA translation repression or degradation thereby controlling protein synthesis. The imperfect binding required for miRNA:mRNA targeting allows for a single miRNA to target hundreds of genes and a single mRNA may have multiple 3-UTR binding sites allowing targeting by multiple miRNAs. Given this depth of complexity, it has been estimated that miRNAs regulate up to 60% of human protein coding genes [Beitzinger and Meister, 2010; Eiring 2010]. While the canonical mechanism of action is translational repression, further adding to the.

[PMC free content] [PubMed] [CrossRef] [Google Scholar] 42

Thursday, August 12th, 2021

[PMC free content] [PubMed] [CrossRef] [Google Scholar] 42. that the mice bearing JLP-silenced xenografts Prodigiosin exhibits reduced tumor volume. Analysis of the xenograft tumor tissues indicate a reduction in the levels of JLP, JNK, phosphorylated-JNK, c-Jun and phosphorylated-c-Jun in JLP-silenced xenografts, thereby correlating the attenuated JLP-JNK signaling node with suppressed tumor growth. Thus, our results identify a critical role for JLP-signaling axis in ovarian cancer and provide evidence that targeting this signaling node could provide a new avenue for therapy. gene, which generates three splice variants namely, JLP (3,921 bp; 1307 amino acids), JIP4 (3426 bp; 1142 amino acids), and SPAG9 (2,268 bp; 766 amino acids) [10]. Of these splice variants, JLP is ubiquitously expressed and provide a scaffold function Prodigiosin for both JNK and p38MAPK [6]. Several studies have reported the overexpression of gene product in many cancers [11C15]. However, the use of antibodies that cross-react with all of the splice variants has raised a major concern regarding the true identity of oncogenic splice variant of fusion gene that contains exon-26 of JLP predicts poor outcome in pediatric acute lymphoblastic leukemia patients establishes a prognostic role for JLP [16]. Potential tumor promoting role for JLP is further substantiated by the cBioPortal analysis of TCGA dataset of ovarian cancer tissue, which indicates that the increased expression of correlates with a reduction in the disease free survival of ovarian cancer patients [17C19]. In addition, the observation that the activation of JNK-signaling predicts poor survival of ovarian cancer patients indirectly points to the potential role of JNK-interacting JLP in disease prognosis [20, 21]. In ovarian cancer, lysophosphatidic acid (LPA) has been characterized as a potent lipid growth factor that elicits both mitogenic and motogenic response and thus promotes ovarian cancer progression and intraperitoneal spread of the disease [22C24]. Based on our previous findings that JLP is involved in LPA-stimulated activation of JNK [7, 8], we hypothesized that the aberrant expression of JLP could promote tumorigenesis or tumor progression in ovarian cancer. This was tested in the present study using ovarian cancer cell lines including those representing Prodigiosin high-grade serous ovarian carcinoma (HGSOC) and ovarian cancer xenografts. Our results indicate that JLP is overexpressed in ovarian cancer tissue compared to adjacent normal ovarian tissue. Increased expression of JLP is also observed in a panel of ovarian cancer cells representing high-grade serous ovarian carcinoma. Ectopic overexpression of JLP stimulates the proliferation as well as the invasive migration of ovarian cancer cells. More interestingly, ectopic expression of JLP promotes long-term survival and clonogenicity in normal fallopian tube-derived epithelial cells. We also demonstrate that JLP Prodigiosin physically interacts with JNK and this interaction is stimulated by LPA. Our results also indicate that JLP is critically required for LPA-stimulated activation of JNK as well as LPA-stimulated proliferation and invasive migration of ovarian cancer cells. Using the mouse xenograft ovarian cancer model, we establish that the silencing of JLP attenuates the activation of JNK signaling module in the tumor tissue along with a resultant reduction in tumor growth and intraperitoneal spread of the disease. Thus, our data presented here identifies, for the Rabbit Polyclonal to DRD1 first time, a tumor-promoting role for JLP in ovarian cancer growth and progression. RESULTS Overexpression of JLP in ovarian cancer Our previous studies have indicated that JLP is required for JNK-mediated oncogenic signaling Prodigiosin by the oncogenes and JNK-signaling in ovarian cancer progression, we investigated whether JLP shows increased expression in ovarian cancer tissues. Using antibodies that do not cross-react with JIP4 or SPAG9, we carried out an immunohistochemical analysis to monitor the expression of JLP in ovarian cancer tissue. As shown in Figure ?Figure1A,1A, ovarian cancer tissue showed an increased expression of JLP compared to normal tissue. Increased expression of JLP could also be observed in ovarian cancer cells isolated from the ascites of patients (Figure ?(Figure1B).1B). Next we analyzed the expression of JLP in a panel of ovarian cancer.